Expand IOVA Menu
IOVA MENU

IOVA Latest Press Releases

-- June 3, 2026 --

Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia Globe Newswire 4:05 PM

-- June 1, 2026 --

How Advanced Drug Delivery Could Improve Existing Cancer Treatments Globe Newswire 8:30 AM
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 Globe Newswire 7:30 AM

-- May 22, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- May 21, 2026 --

Iovance Biotherapeutics to Present at Upcoming Conference Globe Newswire 8:05 AM

-- May 7, 2026 --

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates Globe Newswire 7:05 AM

-- April 27, 2026 --

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 Globe Newswire 8:01 AM

-- April 17, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- March 20, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- February 26, 2026 --

Iovance Biotherapeutics to Present at Upcoming Conferences Globe Newswire 8:00 AM

-- February 24, 2026 --

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates Globe Newswire 7:00 AM
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas Globe Newswire 7:00 AM

-- February 20, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- February 11, 2026 --

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 Globe Newswire 4:05 PM

-- February 5, 2026 --

Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma Globe Newswire 5:15 PM

-- January 16, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- January 12, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH) Globe Newswire 3:31 PM
Market Data Delayed 15 Minutes